The final event of the EURORDIS/RARE IMPACT* initiative entitled "From possible to accessible" is taking place on the 23 November 2020, 2 – 4 pm (CET). During the event the RARE IMPACT report: “Challenges and solutions for improving patient access to advanced therapeutic medicinal products at the European level” will be launched and discussed.
The speakers include the representatives of patients, researchers, policy makers (European Commission), regulators (EMA), HTA (EUnetHTA) and manufacturers. Among the speakers at the event will be Prof. Hans Dieter Volk (Charité – Universitätsmedizin Berlin, BCRT, coordinator of RESTORE).
Participants will have an opportunity to learn about the main findings from the RARE IMPACT* initiative and the speakers will be invited to share their comments and provide ideas about improving access to advanced therapies in Europe.
If you are interested in taking part, the draft agenda is available here and the registration form for the event can be found here. Please note you will receive the webinar link after your registration.
*RARE IMPACT is a multi-stakeholder consortium working to improve patients’ access to gene and cell therapies (advanced therapies). EURORDIS chairs the initiative with the support of Dolon Consulting. Through the engagement with HTA agencies, regulatory bodies, payers, patient groups, clinicians, manufacturers and other experts across Europe the consortium, RARE IMPACT partners aim to identify the challenges and will propose the solutions for a better access to advanced therapies in Europe.